Morgan Stanley
  • Research
  • December 20, 2021

Moderna CEO Stéphane Bancel: Omicron and the Future of mRNA Tech

As the world potentially faces future COVID-19 variants, are we stuck with the virus forever? Morgan Stanley Biotech Equity Analyst Matthew Harrison sits down with Stéphane Bancel, CEO of Moderna.

   

How do today’s most influential C-suite executives navigate a period of historic disruption, marked by a pandemic, tech innovation, rapidly evolving business models, trade tensions and the effects of geopolitics on global business?

In this ongoing series from Morgan Stanley Research, the firm’s equity analysts sit down with leaders at world-class global companies to answer these questions, unpacking broad foundational changes in sectors, industries and markets.

For more Ideas, visit www.morganstanley.com.au/ideas